0.00
price down icon100.00%   -221.38
 
loading
Schlusskurs vom Vortag:
$221.38
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$6.96B
Einnahmen:
$302.00K
Nettoeinkommen (Verlust:
$-117.10M
KGV:
0.00
EPS:
-11.13
Netto-Cashflow:
$-129.13M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$221.42

Cidara Therapeutics Inc Stock (CDTX) Company Profile

Name
Firmenname
Cidara Therapeutics Inc
Name
Telefon
858-752-6170
Name
Adresse
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
73
Name
Twitter
@CidaraThera
Name
Nächster Verdiensttermin
2026-03-05
Name
Neueste SEC-Einreichungen
Name
CDTX's Discussions on Twitter

Compare CDTX vs VRTX, REGN, ARGX, ALNY, INSM

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
CDTX icon
CDTX
Cidara Therapeutics Inc
0.00 6.96B 302.00K -117.10M -129.13M -11.13
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
446.54 113.44B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
772.64 81.68B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
730.25 45.32B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
330.87 43.88B 3.71B 313.75M 465.38M 2.2571
INSM icon
INSM
Insmed Inc
163.52 35.25B 606.42M -1.28B -997.58M -6.403

Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-11-17 Herabstufung JP Morgan Overweight → Neutral
2025-11-17 Herabstufung Morgan Stanley Overweight → Equal-Weight
2025-11-17 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2025-10-16 Eingeleitet Morgan Stanley Overweight
2025-10-10 Eingeleitet JP Morgan Overweight
2025-06-18 Fortgesetzt H.C. Wainwright Buy
2025-03-12 Eingeleitet Citizens JMP Mkt Outperform
2025-01-27 Fortgesetzt Cantor Fitzgerald Overweight
2024-12-13 Eingeleitet RBC Capital Mkts Outperform
2024-11-08 Eingeleitet Guggenheim Buy
2024-08-14 Hochstufung H.C. Wainwright Neutral → Buy
2021-12-03 Fortgesetzt H.C. Wainwright Buy
2021-09-22 Hochstufung WBB Securities Buy → Strong Buy
2021-03-04 Eingeleitet Aegis Capital Buy
2019-09-04 Hochstufung Wedbush Neutral → Outperform
2018-07-26 Eingeleitet Citigroup Buy
2017-04-21 Eingeleitet Raymond James Strong Buy
2017-04-17 Bestätigt H.C. Wainwright Buy
2017-04-12 Eingeleitet Ladenburg Thalmann Buy
2017-04-11 Fortgesetzt Wedbush Outperform
2017-02-22 Bestätigt H.C. Wainwright Buy
2017-02-22 Hochstufung WBB Securities Sell → Hold
2016-12-21 Fortgesetzt Leerink Partners Outperform
2016-12-19 Eingeleitet H.C. Wainwright Buy
2016-09-23 Herabstufung WBB Securities Hold → Sell
2015-10-09 Hochstufung WBB Securities Sell → Hold
2015-05-11 Eingeleitet Jefferies Buy
2015-05-11 Eingeleitet Leerink Partners Outperform
2015-05-11 Eingeleitet Needham Buy
2015-05-11 Eingeleitet Wedbush Outperform
2015-04-23 Eingeleitet WBB Securities Sell
Alle ansehen

Cidara Therapeutics Inc Aktie (CDTX) Neueste Nachrichten

pulisher
Mar 29, 2026

HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - MSN

Mar 29, 2026
pulisher
Mar 25, 2026

Cidara Therapeutics (CDTX) Price Target Increased by 77.93% to 134.30 - MSN

Mar 25, 2026
pulisher
Mar 20, 2026

Cidara Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US1717572069 - marketscreener.com

Mar 20, 2026
pulisher
Mar 20, 2026

Gainers Report: Will Cidara Therapeutics Inc outperform during market ralliesNew Guidance & Proven Capital Preservation Tips - baoquankhu1.vn

Mar 20, 2026
pulisher
Mar 19, 2026

Morgan Stanley Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation - MSN

Mar 19, 2026
pulisher
Mar 18, 2026

Superstring Capital's New Axsome Therapeutics Position: A $6.84M Biopharma InvestmentNews and Statistics - IndexBox

Mar 18, 2026
pulisher
Mar 17, 2026

Merck completes purchase of biopharma company making experimental flu drug - WFMZ.com

Mar 17, 2026
pulisher
Mar 16, 2026

Cidara Therapeutics (CDTX) Price Target Increased by 24.94% to 167.79 - MSN

Mar 16, 2026
pulisher
Mar 13, 2026

CDTX SEC FilingsCidara Theraptcs 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 13, 2026
pulisher
Mar 13, 2026

Breakout Move: Will Cidara Therapeutics Inc outperform during market rallies2026 Retail Activity & Precise Swing Trade Alerts - baoquankhu1.vn

Mar 13, 2026
pulisher
Mar 12, 2026

RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck - The Coloradoan

Mar 12, 2026
pulisher
Mar 08, 2026

Patterns Watch: Can Cidara Therapeutics Inc sustain its profitabilityEarnings Miss & Smart Allocation Stock Tips - baoquankhu1.vn

Mar 08, 2026
pulisher
Mar 07, 2026

Why Cidara Therapeutics Inc. stock could see breakout soonWeekly Market Outlook & High Accuracy Swing Trade Signals - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

Baron Health Care Fund adds TMO, ARQT, and ELAN; exits Cidara Therapeutics, MASI among Q4 moves - MSN

Mar 07, 2026
pulisher
Mar 06, 2026

Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck - MSN

Mar 06, 2026
pulisher
Mar 05, 2026

Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover - Stocktwits

Mar 05, 2026
pulisher
Mar 03, 2026

Baron Health Care Fund Q4 2025 Contributors And Detractors - Seeking Alpha

Mar 03, 2026
pulisher
Feb 26, 2026

Cidara Therapeutics, Inc. (CDTX) Stock Analysis: Is This Biotech Pioneer Poised for Growth? - DirectorsTalk Interviews

Feb 26, 2026
pulisher
Feb 20, 2026

Cidara Therapeutics announces inclusion in the Russell 2000 and 3000 indexes - MSN

Feb 20, 2026
pulisher
Feb 19, 2026

Block Trades: Is Cidara Therapeutics Inc benefiting from innovation trendsMarket Performance Report & Daily Stock Trend Watchlist - baoquankhu1.vn

Feb 19, 2026
pulisher
Feb 19, 2026

Cidara Therapeutics, Inc. (CDTX) Stock Report: Navigating a Biotech Trail with a Market Cap of $6.96 Billion - DirectorsTalk Interviews

Feb 19, 2026
pulisher
Feb 17, 2026

Point72 entities disclose 1.4% Cidara Therapeutics (CDTX) stake in Schedule 13G/A - Stock Titan

Feb 17, 2026
pulisher
Feb 16, 2026

Can Cidara Therapeutics Inc. sustain its profitabilityJuly 2025 Highlights & Low Risk High Reward Ideas - mfd.ru

Feb 16, 2026
pulisher
Feb 15, 2026

Is Cidara Therapeutics Inc. being accumulated by smart money - mfd.ru

Feb 15, 2026
pulisher
Feb 15, 2026

Is Cidara Therapeutics Inc. stock dividend yield sustainableJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - mfd.ru

Feb 15, 2026
pulisher
Feb 13, 2026

How cyclical is Cidara Therapeutics Inc.’s revenue streamIPO Watch & Stepwise Trade Execution Plans - mfd.ru

Feb 13, 2026
pulisher
Feb 13, 2026

Vivo Opportunity funds exit Cidara Therapeutics (CDTX) after merger completion - Stock Titan

Feb 13, 2026
pulisher
Feb 10, 2026

Is Cidara Therapeutics Inc. benefiting from innovation trendsWeekly Trade Review & Weekly High Potential Stock Alerts - mfd.ru

Feb 10, 2026
pulisher
Feb 09, 2026

RedChip Fintech & DATS Conference Replays Now Available Featuring Public Companies Shaping the Future of Digital Finance - USA Today

Feb 09, 2026
pulisher
Feb 09, 2026

Merck Completes Tender Offer and Moves to Acquire Cidara Therapeutics - The Healthcare Technology Report.

Feb 09, 2026
pulisher
Feb 04, 2026

Merck & Co., Inc. Q4 Earnings Call Highlights - MarketBeat

Feb 04, 2026
pulisher
Feb 03, 2026

Portfolio Recap: How sensitive is Cidara Therapeutics Inc to inflationTrade Ideas & Reliable Entry Point Trade Alerts - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 03, 2026

Merck (MRK) Faces One-Time Charge Due to Cidara Acquisition - GuruFocus

Feb 03, 2026
pulisher
Feb 03, 2026

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline - Business Wire

Feb 03, 2026
pulisher
Feb 02, 2026

Aug Highlights: How sensitive is Cidara Therapeutics Inc to inflationQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn

Feb 02, 2026
pulisher
Jan 30, 2026

Biotech Stocks Worth WatchingJanuary 8th - MarketBeat

Jan 30, 2026
pulisher
Jan 29, 2026

Top Biotech Stocks To Watch NowJanuary 2nd - MarketBeat

Jan 29, 2026
pulisher
Jan 29, 2026

Cidara Therapeutics, Inc. (CDTX) Stock Analysis: Understanding the Dynamics of a $6.96 Billion Biotech - DirectorsTalk Interviews

Jan 29, 2026
pulisher
Jan 29, 2026

Is Cidara Therapeutics Inc. on track to beat earnings2025 Pullback Review & Entry and Exit Point Strategies - Mfd.ru

Jan 29, 2026
pulisher
Jan 28, 2026

Published on: 2026-01-28 17:40:21 - mfd.ru

Jan 28, 2026
pulisher
Jan 23, 2026

Promising Biotech Stocks To ConsiderJanuary 4th - MarketBeat

Jan 23, 2026
pulisher
Jan 23, 2026

Pharma News: What is the earnings history of Cidara Therapeutics IncWeekly Risk Report & Low Volatility Stock Recommendations - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 22, 2026

Biotech Stocks To Add to Your WatchlistJanuary 7th - MarketBeat

Jan 22, 2026
pulisher
Jan 22, 2026

Cidara Therapeutics, Inc. (CDTX) Stock Analysis: Navigating the Biotech Landscape with Potential Upside - DirectorsTalk Interviews

Jan 22, 2026
pulisher
Jan 21, 2026

Biotech Stocks To Follow NowJanuary 5th - MarketBeat

Jan 21, 2026
pulisher
Jan 16, 2026

Weekly Earnings: Is Cidara Therapeutics Inc benefiting from innovation trends2025 Key Lessons & High Conviction Trade Alerts - baoquankhu1.vn

Jan 16, 2026
pulisher
Jan 14, 2026

Best Biotech Stocks To Keep An Eye OnJanuary 14th - MarketBeat

Jan 14, 2026
pulisher
Jan 13, 2026

Support Test: Will Cidara Therapeutics Inc stock benefit from upcoming earnings reportsJuly 2025 Movers & Fast Entry Momentum Trade Alerts - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 13, 2026

Whale Trades: Will Cidara Therapeutics Inc. stock benefit from upcoming earnings reportsTrade Analysis Summary & Verified Swing Trading Watchlists - moha.gov.vn

Jan 13, 2026
pulisher
Jan 12, 2026

This Biotech's Stock Price More Than Doubled on Friday. Here's Why. - MSN

Jan 12, 2026
pulisher
Jan 12, 2026

Biotech Stocks To ConsiderJanuary 12th - MarketBeat

Jan 12, 2026

Finanzdaten der Cidara Therapeutics Inc-Aktie (CDTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$27.70
price up icon 4.88%
$50.80
price up icon 5.33%
$47.97
price up icon 3.45%
$88.88
price up icon 4.26%
ONC ONC
$296.97
price up icon 4.54%
$163.52
price up icon 6.65%
Kapitalisierung:     |  Volumen (24h):